Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 7, Issue 5, pp. 1054-1065
PubMed
Published By
Print ISSN
Online ISSN
History
- February 12, 2008
- December 5, 2007
- February 12, 2008
- Published first May 15, 2008.
Copyright & Usage
American Association for Cancer Research
Author Information
- Christian A. Hassig1,
- Kent T. Symons1,
- Xin Guo1,
- Phan-Manh Nguyen1,
- Tami Annable1,
- Paul L. Wash1,
- Joseph E. Payne1,
- David A. Jenkins1,
- Céline Bonnefous1,
- Carol Trotter1,
- Yan Wang1,
- John V. Anzola1,
- Elena L. Milkova1,
- Timothy Z. Hoffman1,
- Sara J. Dozier1,
- Brandon M. Wiley1,
- Alan Saven2,
- James W. Malecha1,
- Robert L. Davis1,
- Jerry Muhammad1,
- Andrew K. Shiau1,
- Stewart A. Noble1,
- Tadimeti S. Rao1,
- Nicholas D. Smith1 and
- Jeffrey H. Hager1
- 1Kalypsys, Inc., San Diego, California, and 2Ida M. and Cecil H. Green Cancer Center, Scripps Green Hospital and Scripps Clinic, La Jolla, California
- Requests for reprints: Christian A. Hassig, Kalypsys, Inc., 10420 Wateridge Circle, San Diego, CA 92121.
May 2008
Volume 7, Issue 5
Volume 7, Issue 5
KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Jump to section
- Article
- Abstract
- Introduction
- Materials and Methods
- Identification of a Novel Series of HDAC Inhibitors
- Characterization of KD5170
- Tumor-Based Pharmacodynamics
- In vivo Efficacy: Monotherapy
- In vivo Efficacy: Combination Therapy
- Discussion
- Disclosure of Potential Conflicts of Interest
- Acknowledgments
- Footnotes
- References
- Figures & Data
- Info & Metrics
Advertisement